Literature DB >> 2954817

Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes.

A Pascual, D Tsukayama, J Kovarik, G Gekker, P Peterson.   

Abstract

Rifapentine uptake by human peritoneal macrophages and polymorphonuclear leukocytes was evaluated and its activity against intracellular Staphylococcus aureus and Staphylococcus epidermidis in both types of phagocytes was compared to that of rifampin, teicoplanin and clindamycin. Uptake of radiolabeled rifapentine by peritoneal macrophages (intracellular/extracellular ratio 61.4 +/- 5.8) and polymorphonuclear leukocytes (intracellular/extracellular ratio 87.6 +/- 3.9) was significantly higher than that of teicoplanin (intracellular/extracellular ratio 40.8 +/- 3.6 and 52.3 +/- 3.2 respectively) and clindamycin (intracellular/extracellular ratio 6.9 +/- 0.4 and 8.3 +/- 0.5 respectively). Rifapentine and rifampin showed the highest activity against intracellular staphylococci in both peritoneal macrophages and polymorphonuclear leukocytes. Clindamycin also showed efficient intracellular activity. In contrast, teicoplanin, which achieved high cellular levels with both types of phagocytes, failed to produce a significant reduction in viable intraphagocytic Staphylococcus epidermidis. On the basis of these findings it is suggested that rifapentine may play a future role in the treatment of certain types of staphylococcal infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954817     DOI: 10.1007/bf02018197

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  19 in total

1.  Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.

Authors:  G L Mandell; T K Vest
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

2.  Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings].

Authors:  A T Birmingham; A J Coleman; M L Orme; B K Park; N J Pearson; A H Short; P J Southgate
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

3.  Comparative uptake of rifampicin and rifapentine (DL473) by human neutrophils.

Authors:  C S Easmon; J P Crane
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

4.  Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis.

Authors:  H A Verbrugh; W F Keane; J R Hoidal; M R Freiberg; G R Elliott; P K Peterson
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

5.  Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes.

Authors:  P K Peterson; J Verhoef; D Schmeling; P G Quie
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

6.  Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria.

Authors:  K Vosbeck; P R James; W Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

7.  Antibiotic uptake by alveolar macrophages of smokers.

Authors:  W L Hand; R M Boozer; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

8.  The effect of teicoplanin on leukocytic activity and intraleukocytic micro-organisms.

Authors:  A Fietta; C Bersani; V De Rose; F M Grassi; G Gialdroni Grassi
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

9.  Treatment of experimental staphylococcal infection with rifampin.

Authors:  M C Lobo; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

10.  The survival of staphylococci within human leukocytes.

Authors:  D E ROGERS; R TOMPSETT
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

View more
  23 in total

1.  Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes.

Authors:  Isabel García; Sofía Ballesta; Concepción Murillo; Evelio J Perea; Alvaro Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Activity of intracellular antibiotics.

Authors:  P Van der Auwera; G Prinz; G Petrikkos
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.

Authors:  A Pascual; I García; S Ballesta; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

Authors:  L Heifets; T Sanchez; J Vanderkolk; V Pham
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.

Authors:  M Ozaki; K Komori; M Matsuda; R Yamaguchi; T Honmura; Y Tomii; I Nishimura; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Effect of amoxycillin and clavulanic acid, alone and in combination, on human polymorphonuclear leukocyte function against Staphylococcus aureus.

Authors:  A Pascual; L Martínez Martínez; J Aragón; E J Perea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

8.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 10.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.